Navigation Links
Mesa Labs Acquires SGM Biotech, Inc.
Date:4/27/2010

LAKEWOOD, Colo., April 27 /PRNewswire-FirstCall/ -- Mesa Laboratories, Inc.  (Nasdaq: MLAB), a Lakewood, Colorado based manufacturer of electronic instruments and disposables, today announced the acquisition of SGM Biotech, Inc., a Montana manufacturer of biological indicator (BI) products.

Under the terms of the transaction, Mesa Labs has acquired all of the outstanding shares of SGM for approximately $12 million in cash, subject to certain net asset adjustments.  In the 12-month period ended March 31, 2010, SGM had unaudited revenues of approximately $6.3 million.  In conjunction with this acquisition, Mesa will also be purchasing the building in Bozeman, Montana currently occupied by SGM.  The addition of SGM is expected to increase Mesa's cash flow significantly.  Excluding deal related costs and amortization expenses, the acquisition is expected to be accretive to earnings for the fiscal year ending March 31, 2011, while including these expenses, the acquisition is expected to have a negligible affect on earnings per share for this period.  By realizing manufacturing synergies between SGM and Mesa's existing BI division, the acquisition is expected to be accretive on both a cash and GAAP basis in subsequent fiscal years.

The acquisition of SGM by Mesa Labs expands and complements Mesa's existing offering of biological indicators through its Raven Labs division.  SGM and Raven are both well established brands in the BI marketplace, with loyal customer followings.  The operational plan going forward will be to maintain both the SGM and Raven brands in the market, operating somewhat independently.  Customers have established their testing protocols around a particular brand and, by maintaining differentiated positions of the two BI brands, it will minimize the impact this acquisition will have on end users.  SGM's BI manufacturing facility will be maintained in Bozeman, Montana, as will Raven's in Omaha, Nebraska.

"We are delighted to welcome SGM Biotech into the Mesa organization," said John J. Sullivan, President and CEO of Mesa Labs.  "SGM has earned an enviable reputation in the BI market as an innovator and manufacturer of high quality products.  By fostering collaboration between our two BI divisions, Raven and SGM, we expect to offer ever-expanding product lines to meet emerging sterilization trends in both industry and healthcare.  By maintaining two distinct divisions, we will be able to offer redundancy in supply that cannot be offered by any other BI manufacturer.  Redundant supply is a critical factor for many of our customers who use our BIs as an integral part of their sterile manufacturing process.  I look forward to working closely with the SGM team in the months ahead as they integrate into the Mesa organization."

"We are pleased to join Mesa Labs, well respected for its product quality and customer service," commented SGM's two shareholders, John R. Gillis and Darlene Hartze.  "We believe this will create access to new markets and distribution channels that will enhance overall corporate objectives.  We are also excited for these expanded horizons that will provide our employees greater opportunities."

About SGM   Founded in 1988, privately held SGM Biotech is a leading manufacturer of biological indicators, which are used for quality control and validation of sterilization processes.  SGM's worldwide customers include pharmaceutical and medical device manufacturers, along with hospitals, clinics and dental offices.  Additional information about SGM and its products can be found at www.sgmbiotech.com.

About Mesa Labs   Founded in 1982, Mesa Labs manufactures instruments and disposable products utilized in connection with industrial applications and healthcare.  Products include DataTrace data loggers and Torqo bottle cap testing instruments for quality control applications in pharmaceutical, food, and medical device manufacturing; Medical meters used for quality control in dialysis clinics; and Raven Biological Indicators used in applications similar to SGM's.  Additional information about Mesa and its products can be found at www.mesalabs.com.

This news release contains forward-looking statements which involve risks and uncertainties.  The Company's actual results could differ materially from those in any such forward-looking statements.  Additional information concerning important factors that could cause results to differ materially from those in any such forward-looking statement is contained in the Company's Annual Report on Form-10K for the fiscal year ended March 31, 2009 as filed with the Securities and Exchange Commission, and from time to time in the Company's other reports on file with the Commission.


'/>"/>
SOURCE Mesa Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
2. Image Solutions, Inc. Acquires Zurich Biostatistics, Inc.
3. U.S. Preventive Medicine Acquires Specialty Disease Management
4. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
5. Nastech Reacquires Teriparatide (Parathyroid Hormone; PTH1-34) Nasal Spray from Procter & Gamble
6. Prescient Medical, Inc. Acquires New Technology to Detect Inflammation in Coronary Blood Vessels
7. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim
8. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim and Manufacturing Facility From PLIVA
9. Wound Management Technologies Acquires Resorbable Orthopedics
10. Bausch & Lomb Acquires the Commercial Assets of Italian Ophthalmic Pharmaceuticals Company Tubilux
11. Kimberly-Clark Acquires Baylis Medical Companys Pain Management Business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
Breaking Medicine Technology:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... TopConsumerReviews.com recently ... of Eyeglasses . , Millions of individuals in the United States and Canada ... become a way to both correct vision and make a fashion statement. Even celebrities ...
(Date:6/26/2016)... ... 26, 2016 , ... PawPaws brand pet supplements owned by Whole ... enhance the health of felines. The formula is all-natural and is made from Chinese ... PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
Breaking Medicine News(10 mins):